InsidersTradesSigma
Follow the ProQR Therapeutics N.V. share price and the full management transaction log of the company, a listed equity based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €327.4m. The latest transaction was disclosed on 3 August 2026 (Acquisition). Among the most active insiders: de Boer Daniel Anton. Every trade is free.
Analysts rate ProQR Therapeutics N.V. Strong Buy (bullish), based on 9 analysts. Average price target: US$8.22.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
ProQR Therapeutics N.V. is a biopharmaceutical company focused on developing treatments for genetic diseases. It specializes in RNA-based therapies to address hereditary disorders.